Hepatitis Monthly

Published by: Kowsar

Association Between Tumor Necrosis Factor-α and the Risk of Hepatic Events: A Median 3 Years Follow-Up Study

Zhi Zhu 1 and Shuofeng Li 1 , *
Authors Information
1 Department of Radiology, Cangzhou Central Hospital, Cangzhou, Hebei Province, China
Article information
  • Hepatitis Monthly: July 2018, 18 (7); e65537
  • Published Online: June 10, 2018
  • Article Type: Research Article
  • Received: December 25, 2017
  • Revised: March 11, 2018
  • Accepted: May 18, 2018
  • DOI: 10.5812/hepatmon.65537

To Cite: Zhu Z, Li S. Association Between Tumor Necrosis Factor-α and the Risk of Hepatic Events: A Median 3 Years Follow-Up Study, Hepat Mon. 2018 ; 18(7):e65537. doi: 10.5812/hepatmon.65537.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609. doi: 10.1053/j.gastro.2012.04.001. [PubMed: 22656328].
  • 2. Effendi K, Harada K, Hashimoto E, Kage M, Koike K, Kondo F. Pathological findings of NASH and NAFLD: for guidebook of NASH and NAFLD, 2015: The Japan society of hepatology. Hepatol Res. 2017:3-10.
  • 3. Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study. Middle East J Dig Dis. 2016;8(2):131-7. doi: 10.15171/mejdd.2016.18. [PubMed: 27252820]. [PubMed Central: PMC4885612].
  • 4. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56(5):1983-92. doi: 10.1002/hep.25915. [PubMed: 22729954].
  • 5. Pais R, Ratziu V. Epidemiology and natural history of nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2015;20(3):221-35.
  • 6. Angulo P. Nonalcoholic fatty liver disease. 2017. p. 565-76.
  • 7. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36(1):22-9. doi: 10.1111/j.1365-2036.2012.05121.x. [PubMed: 22554256]. [PubMed Central: PMC3437221].
  • 8. Lapadat AM, Jianu IR, Ungureanu BS, Florescu LM, Gheonea DI, Sovaila S, et al. Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life. 2017;10(1):19-26. [PubMed: 28255371]. [PubMed Central: PMC5304366].
  • 9. Nasr P, Forsgren MF, Ignatova S, Dahlstrom N, Cedersund G, Leinhard OD, et al. Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology. 2017;153(1):53-55 e7. doi: 10.1053/j.gastro.2017.03.005. [PubMed: 28286210].
  • 10. European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64. doi: 10.1016/j.jhep.2015.04.006. [PubMed: 25911335].
  • 11. Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25(2):291-303. doi: 10.1016/j.bpg.2011.02.003. [PubMed: 21497746].
  • 12. Changchien C, Mwangi I, Yokoo T, Schroeder ME, Bydder M, Hamilton G. Comparison of Rates of Change in Segmental Liver Fat Using MRI-Determined Proton Density Fat Fraction. Radiological Society of North America 2010 Scientific Assembly and Meeting. 2010.
  • 13. Yang YM, Seki E. TNFalpha in liver fibrosis. Curr Pathobiol Rep. 2015;3(4):253-61. doi: 10.1007/s40139-015-0093-z. [PubMed: 26726307]. [PubMed Central: PMC4693602].
  • 14. Koek GH. [Treatment of non-alcoholic fatty liver disease]. Ned Tijdschr Geneeskd. 2011;155. A3181. [PubMed: 21649947].
  • 15. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med. 2004;117(2):87-92. doi: 10.1016/j.amjmed.2004.02.032. [PubMed: 15234643].
  • 16. Zhao L, Wang X, Yang Y. Association between interleukin-6 and the risk of cardiac events measured by coronary computed tomography angiography. Int J Cardiovasc Imaging. 2017;33(8):1237-44. doi: 10.1007/s10554-017-1098-y. [PubMed: 28233119].
  • 17. Hedderich DM, Hasenberg T, Haneder S, Schoenberg SO, Kucukoglu O, Canbay A, et al. Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction. Obes Surg. 2017;27(7):1755-62. doi: 10.1007/s11695-016-2531-3. [PubMed: 28064372].
  • 18. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):521-33. viii. doi: 10.1016/j.cld.2004.04.004. [PubMed: 15331061].
  • 19. Kumar A, Singh AK, Panda PK, Nischal N, Soneja M. Non-alcoholic fatty liver disease diagnosis, grading and staging; a simplified tool for clinicians. J Adv Med. 2017;6(1):15. doi: 10.5958/2319-4324.2017.00003.7.
  • 20. Metrakos P, Nilsson T. Non-alcoholic fatty liver disease-a chronic disease of the 21(st) century. J Biomed Res. 2017. doi: 10.7555/JBR.31.20160153. [PubMed: 28550272].
  • 21. Hammerich L, Tacke F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014;7:297-306. doi: 10.2147/CEG.S43737. [PubMed: 25214799]. [PubMed Central: PMC4158890].
  • 22. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112(12):1785-8. doi: 10.1172/JCI20514. [PubMed: 14679172]. [PubMed Central: PMC297006].
  • 23. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26(1):39-45. doi: 10.1111/j.1478-3231.2005.01191.x. [PubMed: 16420507].
  • 24. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40(1):46-54. doi: 10.1002/hep.20280. [PubMed: 15239085].
  • 25. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Faga E, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology. 2005;42(5):1175-83. doi: 10.1002/hep.20896. [PubMed: 16231364].
  • 26. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. Indian J Clin Biochem. 2013;28(2):141-6. doi: 10.1007/s12291-012-0236-5. [PubMed: 24426199]. [PubMed Central: PMC3613495].
  • 27. Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, et al. Tumor Necrosis Factor-alpha as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinol Metab (Seoul). 2013;28(1):41-5. doi: 10.3803/EnM.2013.28.1.41. [PubMed: 24396649]. [PubMed Central: PMC3811803].
  • 28. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267(3):767-75. doi: 10.1148/radiol.13121360. [PubMed: 23382293].
  • 29. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416-25. doi: 10.1148/radiol.14140754. [PubMed: 25247408]. [PubMed Central: PMC4314291].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments